Get the Stockscreener App
8.61
0.12%
0.010
After Hours:
8.65
0.04
+0.46%
Engene Holdings Inc stock is traded at $8.61, with a volume of 79,977.
It is up +0.12% in the last 24 hours and down -5.07% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$8.60
Open:
$9.01
24h Volume:
79,977
Relative Volume:
0.49
Market Cap:
$438.40M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-26.70M
1W Performance:
+14.80%
1M Performance:
-5.07%
6M Performance:
-33.05%
1Y Performance:
+8.03%
1-Day Range:
$8.20
$9.1499
1-Week Range:
$7.435
$9.1499
52-Week Range:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
8.61 | 438.40M | 0 | -103.21M | -26.70M | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
enGene (NASDAQ:ENGN) Coverage Initiated at Raymond James - MarketBeat
Recent uptick might appease enGene Holdings Inc. (NASDAQ:ENGN) institutional owners after losing 4.2% over the past year - Simply Wall St
enGene to Participate in Upcoming Investor Conferences - Vulcan Advocate
enGene Holdings to Present Cancer Treatment Updates at Major Healthcare Conferences | ENGN Stock News - StockTitan
enGene (NASDAQ:ENGN) Coverage Initiated at JMP Securities - MarketBeat
JMP bullish on Engene stock as non-viral bladder cancer therapy gains traction By Investing.com - Investing.com South Africa
JMP bullish on Engene stock as non-viral bladder cancer therapy gains traction - Investing.com India
(ENGN) Trading Advice - Stock Traders Daily
With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners - Yahoo Finance
Blue Owl Capital Holdings LP Increases Stake in enGene Holdings Inc - GuruFocus.com
enGene files $300M mixed securities shelf - TipRanks
enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Consensus PT from Brokerages - MarketBeat
How the (ENGN) price action is used to our Advantage - Stock Traders Daily
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - BioSpace
enGene to Present Breakthrough Cancer Therapy at Guggenheim Healthcare Conference | ENGN Stock News - StockTitan
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares - Investing.com India
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares By Investing.com - Investing.com South Africa
FY2024 EPS Estimates for enGene Boosted by Leerink Partnrs - MarketBeat
EnGene Announces $60 Million Private Placement Financing - Marketscreener.com
enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Growth in Short Interest - MarketBeat
enGene secures $60 million in private placement By Investing.com - Investing.com Canada
enGene Announces $60 Million Private Placement Financing - citybiz
Why enGene Holdings Stock Is Trading Higher - Benzinga
enGene secures $60 million in private placement - Investing.com
EnGene Holdings Shares Rise After $60M Private Placement - MarketWatch
enGene announces $60M private placement financing - MSN
enGene Holdings Secures $60 Million for Genetic Medicines - TipRanks
EnGene Holdings Inc. announced that it expects to receive CAD 60.148968 million in funding from a group of investors - Marketscreener.com
EnGene Holdings Inc. announced that it expects to receive $60.148968 million in funding from a group of investors - Marketscreener.com
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer - citybiz
enGene Holdings Announces Key Executive Appointments - TipRanks
EnGene Holdings Inc. Announces Executive Changes - Marketscreener.com
enGene CTO Anthony Cheung transitions to CSO, Joan Connolly to succeed - TipRanks
Forbion growth opportunities fund increases stake in Engene Holdings with $3 million purchase - Investing.com Australia
enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Purchases $19,717.50 in Stock - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Average PT from Analysts - MarketBeat
Long Term Trading Analysis for (ENGN) - Stock Traders Daily
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Rises By 130.0% - MarketBeat
(ENGN) Investment Report - Stock Traders Daily
Insider Buys Additional US$57k In enGene Holdings Stock - Yahoo Finance
This trade activity should not be overlooked: enGene Holdings Inc (ENGN) - SETE News
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Engene Holdings Inc Stock (ENGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 29 '23 |
Buy |
9.06 |
10,020 |
90,771 |
2,017,820 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 28 '23 |
Buy |
7.69 |
5,050 |
38,827 |
2,007,800 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 27 '23 |
Buy |
7.17 |
2,750 |
19,711 |
2,002,750 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):